title: Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System.
abstract: Type I and III interferons (IFNs) of the innate immune system belong to a polygenic family, however the individual subtype mediators of the antiviral response in viral infections have been hindered by a lack of reagents. Evaluation studies using different IFN subtypes have distinguished distinct protein properties with different efficacies towards different viruses, opening promising avenues for immunotherapy. This review largely focuses on the application of IFN-α/β and IFN-λ therapies for viral infections, influenza, herpes, HIV and hepatitis. Such IFN subtype therapies may help to cure patients with virus infections where no vaccine exists. The ability of cell types to secrete a number of IFN subtypes from a multi-gene family may be an intuitive counterattack on viruses that evade IFN subtype responses. Hence, clinical use of virus-targeted IFN subtypes may restore antiviral immunity in viral infections. Accumulating evidence suggests that individual IFN subtypes have differential efficacies in selectively activating immune cell subsets to enhance antiviral immune responses leading to production of sustained B and T cell memory. Cytokine therapy can augment innate immunity leading to clearance of acute virus infections but such treatments may have limited effects on chronic virus infections that establish lifelong latency. Therefore, exploiting individual IFN subtypes to select those with the ability to sculpt protective responses as well as reinstating those targeted by viral evasion mechanisms may inform development of improved antiviral therapy.
authors.affiliation: School of Veterinary and Life Sciences, Molecular and Biomedical Sciences, Murdoch University, South Street, Murdoch, Perth, Western Australia, Australia. Electronic address: c.berry@murdoch.edu.au.
authors.forename: Cassandra M
authors.initials: CM
authors.lastname: Berry
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D007113:Immunity, Innate; D016898:Interferon-alpha / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D007372:Interferons / Q000627:therapeutic use*; D014777:Virus Diseases / Q000188:drug therapy* / Q000276:immunology; D007378:Interleukins; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D016899:Interferon-beta; D007372:Interferons; C000624353:interferon-lambda, human; D007378:Interleukins; D000095022:Interferon Lambda
keywords: Virus; evasion; immunotherapy; innate cytokines; interferons; subtypes